Clinical trials: Alzheimer Disease 1
Healthy
A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment
The purpose of this study is to evaluate the safety, tolerability, single-ascending dose (SAD), multiple-ascending dose (MAD), food effect, and pharmacokinetic (PK) Study of TML-6.
- Trial name
- NCT06562114
- Testing
- TML-6 Granules
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Merry Life Biomedical Co., Ltd.
Neurodegenerative Diseases, Alzheimer's Disease
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of…
- Trial name
- NCT05792163
- Testing
- SNP318 (A)
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- SciNeuro
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
The purpose of this study is to evaluate the safety and tolerability of dimebon given to Alzheimer's disease patients currently on a stable dose and regimen of memantine or memantine plus donepezil.
- Trial name
- NCT00829816
- Testing
- Dimebon
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease
Amyloid Beta-peptide 1-40 and Alzheimer's Disease
The combined measurement of Ab42 and tau protein (total and phosphorylated) in the spinal fluid has been shown to be promising in the diagnosis of Alzheimer's disease (AD), and has justified its inclusion new diagnostic criteria.
- Trial name
- ADAB40 (NCT02770482)
- Testing
- spinal fluid collection
- Where
- France
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Alzheimer's Disease
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
This is a Phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7105705 in two participant populations: healthy participants and…
- Trial name
- NCT02820896
- Testing
- RO7105705
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.
This study is designed to investigate the safety, tolerability, and pharmacokinetics of PF-04447943 after single and multiple-dose administration to healthy young adult and elderly Japanese subjects, respectively.
- Trial name
- NCT00959803
- Testing
- PF-04447943
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.
- Trial name
- NCT05667649
- Testing
- RB-ADSC
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Regeneration Biomedical, Inc.
Alzheimer Disease
A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
- Trial name
- NCT05345509
- Testing
- Aricept Tablet, IVL3003
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Alzheimer's Disease, Safety
Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers
The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential
- Conditions
- Alzheimer's Disease, Safety, Tolerability, Blood Concentration
- Trial name
- NCT01348737
- Testing
- AZD3839
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations
A Phase 1, Crossover Study to Evaluate the Pharmacokinetics of Corplex™ Donepezil 10 mg Transdermal Delivery System Applied to Different Body Locations
- Trial name
- NCT03432195
- Testing
- Donepezil TDS
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Corium, Inc.
Healthy Adult Participants, Alzheimer Disease
A Study of GSM-779690T in Healthy Adult Participants
A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy…
- Trial name
- NCT07690228
- Testing
- GSM-779690T
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Acta Pharmaceuticals
Alzheimer Disease
Erythrocyte Complement Receptor 1 and Alzheimer Disease
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the…
- Trial name
- NCT01565434
- Testing
- CR1 impact
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Mild Cognitive Impairment, Alzheimer Dementia
Innate Immunity Stimulation Via TLR9 in Early AD
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD).
- Trial name
- NCT05606341
- Testing
- CpG1018
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Alzheimer Disease
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults…
- Trial name
- NCT05696483
- Testing
- OLX-07010 Active
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Oligomerix, Inc
Alzheimer's Disease
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
The purpose of the study is to determine the highest dose of TPI-287 that is safe and tolerable when administered as an intravenous infusion to participants with mild to moderate Alzheimer's disease (AD), to measure…
- Trial name
- NCT01966666
- Testing
- TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, San Francisco
Alzheimer's Disease
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive…
- Trial name
- NCT02546310
- Testing
- HTL0009936
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Alzheimer Disease
Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)
To evaluate pharmacokinetics, safety and efficacy of SNUBH-NM-333(18F), a new diagnostic radiopharmaceutical for PET imaging of amyloid plaques, in Alzheimer's disease patients and healthy volunteers.
- Trial name
- NCT02149017
- Testing
- SNUBH-NM-333(18F)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Alzheimer Disease (AD)
Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease
The study aims to compare tau targeted radiotracers [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in subjects with normal cognition or prodromal to moderate Alzheimer's disease (AD).
- Trial name
- NCT04566003
- Testing
- [18F]GTP1, [18F]PI-2620, [18F]MK-6240
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.